These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 18852147)

  • 1. Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition.
    Yagi H; Yotsumoto F; Miyamoto S
    Mol Cancer Ther; 2008 Oct; 7(10):3441-51. PubMed ID: 18852147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
    Tang X; Lu M; Li C; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New approach to cancer therapy: heparin binding-epidermal growth factor-like growth factor as a novel targeting molecule.
    Miyamoto S; Yagi H; Yotsumoto F; Horiuchi S; Yoshizato T; Kawarabayashi T; Kuroki M; Mekada E
    Anticancer Res; 2007; 27(6A):3713-21. PubMed ID: 17970033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer.
    Tanaka Y; Miyamoto S; Suzuki SO; Oki E; Yagi H; Sonoda K; Yamazaki A; Mizushima H; Maehara Y; Mekada E; Nakano H
    Clin Cancer Res; 2005 Jul; 11(13):4783-92. PubMed ID: 16000575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy.
    Tsujioka H; Yotsumoto F; Hikita S; Ueda T; Kuroki M; Miyamoto S
    Curr Opin Obstet Gynecol; 2011 Feb; 23(1):24-30. PubMed ID: 20966750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy.
    Miyamoto S; Hirata M; Yamazaki A; Kageyama T; Hasuwa H; Mizushima H; Tanaka Y; Yagi H; Sonoda K; Kai M; Kanoh H; Nakano H; Mekada E
    Cancer Res; 2004 Aug; 64(16):5720-7. PubMed ID: 15313912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
    Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
    Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteolytic activation of heparin-binding EGF-like growth factor by membrane-type matrix metalloproteinase-1 in ovarian carcinoma cells.
    Koshikawa N; Mizushima H; Minegishi T; Eguchi F; Yotsumoto F; Nabeshima K; Miyamoto S; Mekada E; Seiki M
    Cancer Sci; 2011 Jan; 102(1):111-6. PubMed ID: 20946474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of CRM197, a specific inhibitor of HB-EGF, in oral cancer.
    Dateoka S; Ohnishi Y; Kakudo K
    Med Mol Morphol; 2012 Jun; 45(2):91-7. PubMed ID: 22718294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer.
    Tang XH; Deng S; Li M; Lu MS
    Biochem Biophys Res Commun; 2012 Jun; 422(4):676-80. PubMed ID: 22609777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells.
    Wang F; Sloss C; Zhang X; Lee SW; Cusack JC
    Cancer Res; 2007 Sep; 67(18):8486-93. PubMed ID: 17875687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.
    Tang XH; Deng S; Li M; Lu MS
    Tumour Biol; 2016 Apr; 37(4):5521-8. PubMed ID: 26572150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role and mechanism of the regulation of nuclear factor-κB by heparin binding-epidermal growth factor-like growth factor in the induction of paclitaxel resistance of ovarian cancer].
    Tang XH; Lu MS; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2019 Apr; 54(4):255-261. PubMed ID: 31006192
    [No Abstract]   [Full Text] [Related]  

  • 14. LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling.
    Lue HW; Yang X; Wang R; Qian W; Xu RZ; Lyles R; Osunkoya AO; Zhou BP; Vessella RL; Zayzafoon M; Liu ZR; Zhau HE; Chung LW
    PLoS One; 2011; 6(11):e27720. PubMed ID: 22110740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF.
    Sato S; Drake AW; Tsuji I; Fan J
    PLoS One; 2012; 7(12):e51964. PubMed ID: 23251664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian cancer cell heparan sulfate 6-O-sulfotransferases regulate an angiogenic program induced by heparin-binding epidermal growth factor (EGF)-like growth factor/EGF receptor signaling.
    Cole CL; Rushton G; Jayson GC; Avizienyte E
    J Biol Chem; 2014 Apr; 289(15):10488-10501. PubMed ID: 24563483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation.
    Fujiyama S; Matsubara H; Nozawa Y; Maruyama K; Mori Y; Tsutsumi Y; Masaki H; Uchiyama Y; Koyama Y; Nose A; Iba O; Tateishi E; Ogata N; Jyo N; Higashiyama S; Iwasaka T
    Circ Res; 2001 Jan; 88(1):22-9. PubMed ID: 11139469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin-binding EGF-like growth factor enhances the activity of invasion and metastasis in thyroid cancer cells.
    Ota I; Higashiyama S; Masui T; Yane K; Hosoi H; Matsuura N
    Oncol Rep; 2013 Oct; 30(4):1593-600. PubMed ID: 23917679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteration of integrins by heparin-binding EGF-like growth factor in human breast cancer cells.
    Narita T; Kawakami-Kimura N; Sato M; Matsuura N; Higashiyama S; Taniguchi N; Kannagi R
    Oncology; 1996; 53(5):374-81. PubMed ID: 8784471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The EGFR ligands amphiregulin and heparin-binding egf-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer.
    Yasumoto K; Yamada T; Kawashima A; Wang W; Li Q; Donev IS; Tacheuchi S; Mouri H; Yamashita K; Ohtsubo K; Yano S
    Clin Cancer Res; 2011 Jun; 17(11):3619-30. PubMed ID: 21482691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.